Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily teriparatide followed by one subcutaneous injection of denosumab experienced a moderate gain in ...

Osteoporosis (OP) is the most common multifactorial metabolic bone disorder worldwide, and is a major public health concern among the elderly and in postmenopausal women. It is therefore of global ...

During the first 12 weeks of treatment, 41.1% of women on denosumab developed severe hypocalcemia compared with 2.0% of those taking oral bisphosphonates, reported a group of largely FDA researchers ...

A twice-yearly injection of denosumab improved spinal bone mineral density among individuals with osteoporosis caused by transfusion-dependent thalassemia, according to a randomized phase 2b study ...

The U.S. Food and Drug Administration (FDA) approved the expanded indication of Prolia for the treatment of osteoporosis associated with newly initiating or sustained systemic glucocorticoid therapy ...

November 10, 2010 — In advanced breast cancer patients who have bone metastases, the novel biologic denosumab was superior to zoledronic acid in preventing skeletal-related events (SREs) and renal ...

Correcting for Discretionary Treatment Crossover in an Analysis of Survival in the Breast International Group BIG 1-98 Trial by Using the Inverse Probability of Censoring Weighted Method Bone ...

“In a hypothetical health plan covering 1 million lives, adding biosimilar denosumab to a health plan formulary may contribute to significant cost savings; savings can be reinvested to further expand ...

JERSEY CITY, N.J., March 3, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO ® (CT-P41, denosumab-bmwo) and OSENVELT ® (CT-P41, ...

BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of ...

Sandoz shared that it has reached agreement with Amgen to resolve all patent disputes between the two companies relating to the Food and Drug Administration approved Sandoz denosumab biosimilars.